References
- Bystryn, J.C., Rudolf, J.L. Pemphigus. Lancet. 2005, 366 (9479), 61–73.
- Femiano, F. Pemphigus vulgaris: Recent advances in our understanding of its pathogenesis. Minerva Stomatol. 2007, 56 (4), 215–223.
- Shamim, T., Varghese, V.I., Shameena, P.M., Sudha, S. Pemphigus vulgaris in oral cavity: Clinical analysis of 71 cases. Med. Oral Pathol. Oral Cir. Bucal. 2008, 13 (10), 622–626.
- Eversole, L.R., Kenney E.B., Sabes, W.R. Oral lesions as the initial sign in pemphigus vulgaris. Oral Surg. Oral Med. Oral Pathol. 1972, 33 (3), 354–361.
- Regezi, J.A., Sciubba, J.J. Oral Pathology: Clinical Pathologic Correlations, 3rd ed. Philadelphia:W.B. Saunders, 1999, pp. 1–29.
- Ioannides, D., Lazaridou, E., Rigopoulos, D. Pemphigus. J. Eur. Acad. Dermatol. Venereol. 2008, 22 (12), 1478–1496.
- Jamora, M.J., Jiao, D., Bystryn, J.C. Antibodies to desmoglein 1 and 3, and the clinical phenotype of pemphigus vulgaris. J. Am. Acad. Dermatol. 2003, 48 (6), 976–977.
- Shirakata, Y., Amagai, M., Hanakawa, Y. et al. Lack involvement in pemphigus foliaceus may be due to low expression of desmoglein 1. J. Invest. Dermatol, 1998, 110 (1), 76–78.
- Tong, J.C., Tan, T.W., Sinha, A.A., Ranganathan, S. Prediction of desmoglein-3 peptides reveals multiple shared T-cell epitopes in HLA DR4- and DR6-associated pemphigus vulgaris. BMC Bioinformatics, 2006, 18, 7.
- Futei, Y., Amagai, M., Ishii, K., Kuroda-Kinoshita, K. et al. Predominant IgG4 subclass in autoantibodies of pemphigus vulgaris and foliaceus. J. Dermatol. Sci, 2001, 26 (1), 55–61.
- Bhol, K., Natarajan, K., Nagarwalla, N. et al. Correlation of peptide specificity and IgG subclass with pathogenic and nonpathogenic autoantibodies in pemphigus vulgaris: A model for autoimmunity. Proc. Natl. Acad. Sci. U. S. A, 1995, 92 (11), 5239–5243.
- Amagai, M., Hashimoto, T., Shimizu, N., Nishikawa, T. Absorption of pathogenic autoantibodies by the extracellular domain of pemphigus vulgaris antigen (Dsg3) produced by baculovirus. J. Clin. Invest. 1994,94 (1), 59–67.
- Hashimoto T. Recent advances in the study of the pathophysiology of pemphigus. Arch. Dermatol. Res. 2003, 295 (1), 2–11.
- Calkins, C.C., Setzer, S.V., Jennings, J.M. et al. Desmoglein endocytosis and desmosome disassembly are coordinated responses to pemphigus autoantibodies. J. Biol. Chem, 2006, 281 (11), 7623–7634.
- Cirillo, N., Lanza, M., De Rosa A., et al. At least three phosphorylation events induced by pemphigus vulgaris sera are pathogenically involved in keratinocyte acantholysis. Int. J. Immunopathol. Pharmacol, 2008,21 (1), 189–195.
- Chernyavsky, AI., Arredondo, J., Kitajima, Y. et al. Desmoglein versus non-desmoglein signaling in pemphigus acantholysis: Characterization of novel signaling pathways downstream of pemphigus vulgaris antigens. J. Biol. Chem, 2007, 282 (18), 13804–13812.
- Berkowitz, P., Chua, M., Liu, Z. et al. Autoantibodies in the autoimmune disease pemphigus foliaceus induce blistering via p38 mitogen-activated protein kinase-dependent signaling in the skin. Am. J. Pathol, 2008, 173 (6), 1628–1636.
- Yamamoto, Y., Aoyama, Y., Shu, E. et al. No activation of urokinase plasminogen activator by anti-desmoglein 3 monoclonal IgG antibodies in cultured human keratinocytes. J. Dermatol. Sci, 2007, 47 (2), 119–125.
- Feliciani, C., Toto, P., Wang, B. et al. Urokinase plasminogen activator mRNA is induced by IL-1alpha and TNF-alpha in in vitro acantholysis. Exp. Dermatol, 2003, 12 (4), 466–471.
- Schuh, T., Besch, R., Braungart, E. et al. Protease inhibitors prevent plasminogen-mediated, but not pemphigus vulgaris-induced, acantholysis in human epidermis. Biol. Chem, 2003, 384 (2), 311–315.
- Aoyama, Y., Owada, M.K., Kitajima, Y. A pathogenic autoantibody, pemphigus IgG, induces phosphorylation of desmoglein 3, and its dissociation from plakoglobin in cultured keratinocytes. Eur. J. Immunol. 1999, 29 (7), 2233–2240.
- de Bruin R., Caldelari, A., Williamson, L., et al. Plakoglobin-dependent disruption of the desmosomal plaque in pemphigus vulgaris. Exp. Dermatol, 2007, 16 (6), 468–475.
- Williamson, L., Raess, NA., Caldelari, R. et al. Pemphigus vulgaris identifies plakoglobin as key suppressor of c-Myc in the skin. EMBO J, 2006, 25 (14), 3298–3309.
- Koch, J., Foekens, J., Timmermans, M. et al. Human VAT-1: A calcium-regulated activation marker of human epithelial cells. Arch. Dermatol. Res, 2003, 295 (5), 203–210.
- Qian, Y., Diaz, L.A., Ye, J., Clarke S.H. Dissecting the anti- desmoglein autoreactive B cell repertoire in pemphigus vulgaris patients. J. Immunol, 2007, 178 (9), 5982–5990.
- Takahashi, H., Amagai, M., Nishikawa, T. et al. Novel system evaluating in vivo pathogenicity of desmoglein 3-reactive T cell clones using murine pemphigus vulgaris. J. Immunol, 2008, 181 (2), 1526–1535.
- Veldman, C., Höhne, A., Dieckmann, D. et al. Type I regulatory T cells specific for desmoglein 3 are more frequently detected in healthy individuals than in patients with pemphigus vulgaris. J. Immunol, 2004, 172 (10), 6468–6475.
- Nguyen, V.T., Ndoye, A., Grando, S.A. Novel human 9 acetylcholine receptor regulating keratinocyte adhesion is targeted by pemphigus vulgaris autoimmunity. Am. J. Pathol. 2000, 157(4), 1377–1391.
- Nguyen, V.T., Arredondo, J., Chernyavsky, A.I. et al. Pemphigus vulgaris acantholysis ameliorated by cholinergic agonists. Arch. Dermatol, 2004, 140 (3), 327–334.
- Chernyavsky, AI., Arredondo, J., Piser, T. et al. Differential coupling of M1 muscarinic and alpha7 nicotinic receptors to inhibition of pemphigus acantholysis. J. Biol. Chem, 2008, 283 (6), 3401–3408.
- Mihai, S., Sitaru, C. Immunopathology and molecular diagnosis of autoimmune bullous diseases. J. Cell Mol. Med. 2007, 11 (3), 462–481.
- Joly, P., Mouquet, H., Roujeau, J.C. et al. A single cycle of rituximab for the treatment of severe pemphigus. N. Engl. J. Med, 2007, 357 (6), 545–552.
- Faurschou, A., Gniadecki, R. Two courses of rituximab (anti-CD20 monoclonal antibody) for recalcitrant pemphigus vulgaris. Int. J. Dermatol. 2008, 47 (3), 292–294.
- Allen, K.J., Wolverton, S.E. The efficacy and safety of rituximab in refractory pemphigus: A review of case reports. J. Drugs Dermatol. 2007, 6 (9), 883–889.
- Kanduc, D. Peptimmunology: Immunogenic peptides and sequence redundancy. Curr. Drug Discov. Technol, 2005, 2 (4), 239–244.
- Hacker-Foegen, M.K., Janson, M., Amagai, M. Pathogenicity and epitope characteristics of anti-desmoglein-1 from pemphigus foliaceus patients expressing only IgG1 autoantibodies. J. Invest. Dermatol. 2003, 121 (6), 1373–1378.
- Lucchese, A., Mittelman. A., Lin, M.S. et al. Epitope definition by protomic similarity analysis: Identification of the linear determinant of anti-Dsg3 MAb 5h10. J. Transl. Med, 2004, 2, 43.
- Kanduc, D. Defining peptide sequences: From antigenicity to immunogenicity through redundancy. Curr. Pharmacogenomics, 2006, 4, 33–37.
- Angelini, G., Bonamonte, D., Lin, MS. et al. Characterization of polyclonal antibodies raised against a linear peptide determinant of desmoglein-3. J. Exp. Ther. Oncol, 2005, 5 (1), 1–7.
- Angelini, G., Bonamonte, D., Lucchese, A. et al. Preliminary data on Pemphigus vulgaris treatment by a proteomics-defined peptide: A case report. J. Transl. Med, 2006, 24, 4, 43.